AACR Annual Meeting 2019
UFHCC Speakers and Presenters at AACR
UFHCC will have a great presence at the upcoming American Association for Cancer Research Annual Meeting on March 29-April 3, 2019, in Atlanta, GA.
AACR is a premier event in cancer research. This year it will focus on integrative science, global impact and individualized patient care. There will be sessions covering the latest discoveries in population science and prevention, cancer biology and genomics, microbiome, drug discovery, immunotherapy, tumor microenvironment, metabolism, new quantitative approaches, clinical and translational research, and much more. The full conference program is available here.
We are going to have 46 posters featuring UFHCC research and collaborations, two conference speakers from our distinguished faculty, and a professional development session.
Dr. Christian Jobin will be presenting at the educational session on March 29, 2019, on the role of gut microbiome in cancer. He will talk about cancer functionalities of the microbiome and strategies for dynamic monitoring of microbiome members and their products.
Dr. Folakemi Odedina will be chairing the educational session on cancer health disparities and presenting on use of prospective approaches in characterizing cancer registry data on March 30, 2019.
Dr. Jose Trevino will be part of career development panel for students, postdocs and junior faculty on April 1, 2019.
AACR is a great opportunity to engage with your colleagues and learn about the latest research. If you are attending, visit the lectures, stop by the poster sessions and share with others who might interested in topics presented by our researchers.
Speakers
March 29
Session: ED35 – Modulating the Gut Microbiome to Treat Dysbiosis and Cancer
Presentation: Cancer therapeutics: A view from the microbiota
March 29, 2019, 3:00 p.m.
Room A313 – Georgia World CC
Christian Jobin, Ph.D., Univ. of Florida, Gainesville, FL
March 30
Session: ED05. Characterizing Cancer Disparities Nationally and Internationally Using Publicly Available Data: Recent Advances
Presentation: Use of prospective approaches to characterize cancer registry data
March 30, 2019, 8 a.m.
Room A313 – Georgia World CC
Folakemi T. Odedina. Session Chairperson, Univ. of Florida Health Cancer Center, Orlando, FL
Session: PAS01. Fourteenth Annual AACR Undergraduate Student Caucus and Poster Competition
Presentation: Professional Development Panel and Q&A
March 30, 2019, 9 a.m.
Grand Ballroom – Omni Hotel
Jose G. Trevino II. Univ. of Florida, Gainesville, FL
Posters
March 31
Session: ADR01. The Science of Cancer Health Disparities
Presentation: Prostate cancer risk factors and genomic characterization in West African Black men using epidemiology and NGS: Findings from the CaPTC
1 p.m.
Room B401 – Georgia World CC
Faruk Mohammed, Folakemi T. Odedina, Clayton Yates, Damali N. Martin, Sani Ibrahim, […], Mohammed Dauda Maigatari. Ahmadu Bello University, Zaria, Nigeria, University of Florida, Gainesville, FL, Tuskegee University, Tuskegee, AL, National Cancer Institute, Bethesda, MD, Ahmadu Bello University, Zaria, Nigeria, Georgia College and Satate University, Milledgeville, GA, Federal Medical Center, Abeokuta, Nigeria, University of South Florida, Tampa, FL, National Hospital, Abuja, Nigeria, University of Ilorin, Ilorin, Nigeria, Lagos State University Teaching Hospital, Ikeja, Nigeria
Session: PO.MCb11.01 Targeting Oxidative Stress and Senescence (Section 38)
Presentation: 903 / 10 – Real-time imaging of cellular senescence in living animals
1 p.m.
Lina Cui. University of Florida, Gainesville, FL
Session: PO.ET04.02. New Molecular Targets (Section 15)
Presentation: 378 / 10 – HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT and RTK signaling
1 p.m.
Fernanda Faiao-Flores1, Michael Emmons1, Michael Durante2, Biswarup Saha1, Bin Fang1, John Koomen1, Srikumar Chellappan1, Silvya Maria-Engler3, Jonathan Licht4, William Harbour5, Keiran Smalley1. 1The Moffitt Cancer Center & Research Institute, Tampa, FL; 2Bascom Palmer Eye Institute, Miami, FL; 3University of São Paulo, Brazil; 4University of Florida, Gainesville, FL; 5University of Miami Miller School of Medicine, Miami, FL
Session: PO.ET04.02 New Molecular Targets (Section 15)
Presentation: 392 / 24 – LKB-inactiviated lung cancer cells exhibit dependency on INSL4 signaling
1 p.m.
Rongqiang Yang, Steven W. Li, Zirong Chen, Xin Zhou, Wei Ni, Dongtao A. Fu, Jianrong Lu, Frederic J. Kaye, Lizi Wu. University of Florida, Gainesville, FL
Section: PO.EP01.04. Biomarkets in Risk and Outcomes (Section 26)
Presentation: 591 / 5 – Ciculating testosterone in modifying the association of BMI change rate with serum PSA in prostat cancer-free men with initial-PSA less than 4 ng/mL
1 p.m.
Kai Wang1, Mattia Prosperi2, Peihua Qiu2, Ting-Yuan David Cheng2, Victoria Y. Bird2, Xinguang Chen2, Mingyang Song1. 1Harvard University, Boston, MA; 2University of Florida, Gainesville, FL
April 1
Session: PO.ET06.09. Novel Targets and Pathways (Section 14)
Presentation: 1294 / 9 – Differential sigma-2 receptor-mediated metabolic simulative and apoptotic effects of monovalent CM571 and its homo-bivalent counterpart, MAM03055A
8 a.m.
Cheri Z. Liu1, Bridget M. McVeigh1, Marco Mottinelli2, Hilary E. Nicholson1, Christopher R. McCurdy2, Wayne D. Bowen1. 1Brown University, Providence, RI; 2University of Florida, Gainesville, FL
Session: PO.ET06.09. Novel Targets and Pathways (Section 14)
Presentation:1310 /25 – Abrogation of KRas-addcited tumors by GSK3 suppression-mediated upregulation of β-catenin and c-myc
8 a.m.
Aslamuzzaman Kazi1, Shengyan Xiang1, Hua Yang1, Daniel Delitto2, Jose Trevino2, Rays H. Y. Jiang3, Muhammad Ayaz1, Harshani Lawrence1, Perry Kennedy1, Said M. Sebti1. 1Moffitt Cancer Center, Tampa, FL; 2University of Florida, Gainesville, FL; 3University of South Florida, Tampa, FL
Session: PO.IM01.03. Suppressive Myeloid Cells (Section 24)
Presentation: 1521 / 17 – Tumor-produced hyaluronan contributes to the formation tolerogenic immunosuppressive microenvironment
8 a.m.
Paul R. Dominguez-Gutierrez, Paul Crispen, Sergei A. Kusmartsev. Univ. of Florida College of Medicine, Gainesville, FL
Session: PO.TB06.12. Tumor immune Interactions (Section 9)
Presentation: 1194 / 21 – Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis
8 a.m.
Tyler J. Wildes, Catherine T. Flores, Bayli DiVita Dean, Adam Grippin, Kyle Dyson, Duane A. Mitchell. University of Florida, Gainesville, FL
Session: POMCB07.01. DNA Damage and Repair 1 (Section 35)
Presentation: 1758 / 23 – Splicing component ISY1 interacts with APE1 and regulates base excision repair
8 a.m.
Aruna Jaiswal1, Elizabeth Williamson1, Bhavita Patel2, Gayathri Srinivasan1, Kimi Kong1, Carrie Lomelino2, Satya Narayan2, Robert Hromas1. 1UT Health Science Center San Antonio, San Antonio, TX; 2University of Florida, Gainesville, FL
Session: PO.IM02.08. Cancer Vaccines and Intratumoral Immunomodulation (Section 22)
Presentation: 1465 / 20 – Priming immunity against SCLC with oncolytic virotherapy
8 a.m.
Patrick Kellish1, Connor Hartzell1, Daniil Shabashvili1, Masmudur M. Rahman2, Maria V. Guijarro1, Akbar Nawab1, Grant McFadden2, Frederic J. Kaye1, Maria Zajac-Kaye1. 1University of Florida, Gainesville, FL; 2Arizona State University, Tempe, AZ
Session: PO.BSB02.03. Convergence Science for Tumor Biology, Molecular Biology, and Microenvironment (Section 30)
Presentation: 2456 / 21 – NetZen: A comprehensive network-based pathway and target discovery platform
1 p.m.
Son Le, Alberto Riva, Changwang Deng, David D. Tran. University of Florida, Gainesville, FL
Session: PO.CL.11.11. Circulating and Cell-free Biomarkets for Diagnosis and Monitoring of Cancer 3 (Section 18)
Presentation: 2216 / 5 – Circulating tumor cell isolation based on both physical & biological properties
1 p.m.
Hugh Fan, Kangfu Chen, Pablo Dopico, Thomas George. Univ. of Florida, Gainesville, FL
Session: LBPO.TB02. Late-Breaking Research: Tumor Biology 2 (Section 41)
Presentation: LB-141 / 17 -CIMP is associated with altered microbiota composition in colorectal cancer patients
1 p.m.
Pyoung Hwa Park1, Raad Z. Gharaibeh2, Lauren Cole1, Ang Sun1, Woonbok Chung1, Jaroslav Jelinek1, Jillian L. Pope2, Christian Jobin2, Jean-Pierre J. Issa1. 1Temple University, Philadelphia, PA; 2University of Florida, Gainesville, FL
Session: PO.CL06.05. Combination Immunotherapies 2 (Section 19)
Presentation: 2257 / 16 – Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9
1 a.m.
James J. Lee1, Greg Yothers2, Thomas J. George3, Marwan G. Fakih4, Atrayee Basu Mallick5, Edith P. Mitchell6, James L. Wade, III7, John C. Krauss8, Omar R. Kayaleh9, Dwight E. Heron1, Carmen J. Allegra3, Corey Lipchik10, Huichen Feng10, Marion Joy10, Ashok Srinivasan10, Katherine L. Pogue-Geile10, Peter C. Lucas11, Sarah E. Warren12, Alessandra Cesano12, Samuel A. Jacobs10. 1NSABP Foundation, Inc, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA; 2NSABP Biostatistical Center, and The University of Pittsburgh, Pittsburgh, PA; 3NSABP Foundation, Inc, and University of Florida Health, Gainesville, FL; 4NSABP Foundation, Inc, and The City of Hope Comprehensive Cancer Center, Duarte, CA; 5NSABP Foundation, Inc, and Thomas Jefferson University Hospital, Philadelphia, PA; 6NSABP Foundation, Inc, and The Kimmel Cancer Center at Thomas Jefferson University Hospital, Pittsburgh, PA; 7NSABP Foundation, Inc, and Decatur Memorial Hospital, Decatur, IL; 8NSABP Foundation, Inc, and The University of Michigan, Ann Arbor, MI; 9NSABP Foundation, Inc, and UF Cancer Center at Orlando Health, Orlando, FL; 10NSABP Foundation, Inc, Pittsburgh, PA; 11NSABP Foundation, Inc, and The University of Pittsburgh School of Medicine, Pittsburgh, PA; 12NanoString Technologies, Inc., Seattle, WA
Session: PO.TB01.04. Models and Drug Discovery (Session 4)
Presentation: 1922 / 6 – MYB mimic peptides targeting human and murine MYB-NFIB positive tumor cells
1 p.m.
Yue Jiang1, Lauren Forbes2, Jianping Li1, Shelby Freeberg1, Chunxia Cao1, Maria Zajac-Kaye1, Jonathan Licht1, Alex Kentsis2, Frederic Kaye1. 1University of Florida, Gainesville, FL; 2Memorial Sloan Kettering Cancer Center, New York, NY
Session: PO.MCB04.02. Oncogenic Transcription Factor Function (Section 37)
Presentation: 2612 / 18 – Roles of USF1 in breast tumorigenesis and disease progression
1 p.m.
Jessica Lewis, Iqbal Mahmud, Guimei Tian, Daiqing Liao. University of Florida College of Medicine, Gainesville, FL
Session: PO.TB01.04. Models and Drug Discovery (Section 4)
Presentation: 1923 / 7 – KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to comination of trametinib ™, neratinib (N), and traztuzumab (Tz)
1 p.m.
Rekha Pal1, Ashok Srinivasan1, Peter C. Lucas1, Carmen J. Allegra2, Angela M. Davies3, Alshad S. Lalani4, Samuel A. Jacobs1, Katherine L. Pogue-Geile1. 1NSABP Foundation, Inc., Pittsburgh, PA; 2NSABP Foundation, Inc., and The University of Florida Health, Pittsburgh, PA; 3Champions Oncology, MD; 4Puma Biotechnology, Inc., CA
Session: PO.ET03.03. Drug Resistance 3 (Section 11)
Presentation: 2094 / 1 – Prostaglandin E receptor 3 resistance to tumor treating fields in glioblastoma cells
1 p.m.
Dongjiang Chen1, Son Le1, Nagheme Thomas1, Changwang Deng1, Dan Jin1, Mathew Sebstian1, Jie Ren2, David Tran1. 1Division of Neuro-Oncology, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lilian S. Wells Department of Neurological Surgery, University of Florida, Gainesville, FL; 2Shanghai Jiaotong University School of Medicine, Shanghai, China
Session: PO.MCB02.03. BCL-2 Family Proteins (Section 32)
Presentation: 2493 / 3 – Disulfide bond disproportionation agents activates the death receptor 5 pathway to kill highly resistant breast cancer
1 p.m.
Mengxiong Wang, Renan B. Ferreira, Mary E. Law, Bradley J. Davis, Elham Yaaghubi, Amanda F. Ghilardi, Edgardo Rodriguez, Chi-Wu Chiang, Satya Narayan, Coy Heldermon, Ronald K. Castellano, and Brian K. Law. University of Florida, Gainesville, FL
FO 13. The Science of Global Community Outreach
5 p.m.
Georgia Ballroom 1 – Building C – GWCC
Folakemi T. Odedina, Ph.D, Moderator, Univ. of Florida Health Cancer Center, Orlando, FL
PAS03- Workforce Development: Professional Enhancement and Career Advancement
6:30 – 8:30 p.m.
Centennial Hyatt
Jose G. Trevino II, M.D., Mentor, Univ. of Florida, Gainesville, FL
April 2
Seession: PO.ET06.03. Novel Antitumor Agents 1 (Section 14)
Presentation: 3088 / 22 – Farnesyl/geranylgeranyl transferase dual inhibitor thwarts mutant KRas-driven patient-derived pancreatic tumors
8 a.m.
Aslamuzzaman Kazi1, Shengyan Xiang1, Hua Yang1, Liwei Chen1, Perry Kennedy1, Muhammad Ayaz1, Steven Fletcher2, Christopher Cummings3, Harshani Lawrence1, Francisca Beato1, Ya’an Yang4, Michael P. Kim4, Andrea Delitto5, Patrick Underwood5, Jason B. Fleming1, Jose Trevino5, Andrew D. Hamilton3, Said M. Sebti1. 1Moffitt Cancer Center, Tampa, FL; 2University of Toronto, Ontario, ON, Canada; 3Yale University, New Haven, CT; 4University of Texas MD Anderson Cancer Center, Houston, TX; 5University of Florida, Gainesville, FL
Section: POCT05. Phase II-III Clinical Trials: Part 1 (Section 16)
Presentation: CT154 /20 – Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
8 a.m.
Paul G. Richardson1, Albert Oriol2, Alessandra Larocca3, Paula Rodriguez Otero4, Jan Moreb5, Joan Bladé6, Hani Hassoun7, Michele Cavo8, Adrián Alegre9, Amitabha Mazumder10, Christopher Maisel11, Agne Paner12, Xavier Leleu13, Jeffrey A. Zonder14, Johan Harmenberg15, Sara Thuresson15, Hanan Zubair15, María-Victoria Mateos16. 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Hospital Germans Trias i Pujol, Badalona, Spain; 3A.O.U. Città della Salute e della Scienza di Torino – S.C. Ematologia U, Torino, Italy; 4Clínica Universidad de Navarra, Pamplona, Spain; 5University of Florida Health Cancer Center, Gainesville, FL; 6Hospital Clínica de Barcelona – Servicio de Onco-Hematología, Barcelona, Spain; 7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; 8Policlinico S. Orsola Malpighi, Bologna, Italy; 9Hospital Universitario La Princesa, Madrid, Spain; 10Innovative Clinical Research Institute, Whittier, CA; 11Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX; 12Rush University Medical Center, Chicago, IL; 13CHU de Poitiers, Poitiers, France; 14Karmanos Cancer Institute, Detroit, MI; 15Oncopeptides AB, Stockholm, Sweden; 16Hospital Clinico Universitario de Salamanca, Salamanca, Spain
Session: PO.IM02.11. Novel Immunomodulatory Agents 1 (Section 25)
Presentation: 3280 / 30 – TTFIelds induces immunogenic cell death and STING pathway activation through cytoplasmic double-stranded DNA in glioblastoma cells
8 a.m.
Dongjiang Chen, Nagheme Thomas, David D. Tran. University of Florida, Gainesville, FL
Session: PO.MCB10.06. Noncoding RNAs 2 (Section 38)
Presentation: 3583 / 18 – Differential expression of noncoding RNAs in black compared with white laryngeal cancers
8 a.m.
Kristianna Fredenburg, Jinmai Jiang, Tom Schmittgen. University of Florida, Gainesville, FL
Session: PO.PR02.01. Clinical Prevention, Early Detection, and Interception 1 (Section 28)
Presentation: 3333 / 23 – Potential of kava in reducing lung cancer risk, tobacco use, and associated disparities
8 a.m.
Chengguo Xing1, Yi Wang1, Naomi Fujioka2, Sreekanth Narayanapillai1, Junxuan Lu3. 1Univ. of Florida, Gainesville, FL; 2Univ. of Minnesota, Minneapolis, MN; 3Penn State University, Hersey, PA
Session: PO.ET03.04 Drug Resistance 4 (Section 12)
Presentation: 3023 / 15 – Clonal expansion of RP53 mutated cells is associated with chemoresistance in acute myeloid leukemia
8 a.m.
Bowen Yan, Yi Qiu. of Florida College of Medicine, Gainesville, FL
Session: PO.TB04.05. Invasion and Migration 1 (Session 5)
Presentation: 2849 / 5 – Axl: A promising therapeutic target that leads to multimodal inhibition of the metastatic pathway
8 a.m.
Mai Tanaka, Dietmar W. Siemann. University of Florida, Gainesville, FL
Session: PO.MCB01.05. Cell Signalling 1 (Section 33)
Presentation: 3439 / 10 – Sulindac sulfide as a gamma secretase modifier to target triple negative breast cancer
8 a.m.
Fokhrul Hossain1, Deniz A Ucar1, Samarpan Majumder1, Margarite Matossian2, Keli Xu3, Yong Ran4, Lisa Minter5, Yaguang Xi1, Matthew Burow2, Todd Golde4, Barbara Osborne5, Lucio Miele1. 1LSUHSC, New Orleans, LA; 2Tulane University, New Orleans, LA; 3University of Mississippi Medical Center, Jackson, MS; 4University of Florida, Gainesville, FL; 5UMass Amherst, Amherst, MA
Session: PO.MCB09.06. Cancer Genomics 4 (Section 32)
Presentation: 3407 / 8 – Development of a chemokine signature identifying dMMR patients (pts) with poor prognosis
8 a.m.
Ying Wang1, Rim S. Kim1, Corey Lipchik1, Ashok Srinivasan1, Huichen Feng1, Nan Song1, Carmen J. Allegra2, Patrick G. Gavin1, Samuel A. Jacobs1, Norman Wolmark3, Peter C. Lucas4, Katherine L. Pogue-Geile1. 1NSABP Foundation, Inc., Pittsburgh, PA; 2NSABP Foundation, Inc., and University of Florida Health, Gainesville, FL; 3NSABP Foundation, Inc., and Allegheny Health Network Cancer Institute, Pittsburgh, PA; 4NSABP Foundation, Inc., and University of Pittsburgh School of Medicine, Pittsburgh, PA
Session: PO.ET01.04. New Target Identification (Section 13)
Presentation: 3042 / 4 – Splicing repressorHNRNPC is an indispensable and ‘druggable’ target in acute myeloid leukemia
8 a.m.
Vindhya Vijay1, Amy Meacham1, Lauren Katzell1, Aaron Winer1, Jesse Terrell1, Vincent Archibald1, Jodi Bubenik1, Alberto Riva1, Jon Boatwright1, Cristina Tognon2, Jeffrey Tyner2, Brian Druker2, Christopher Cogle1.1University of Florida, Gainesville, FL; 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR
Session: PO.TB08.01. Targets and Therapies in Pediatric Cancer (Section 6)
Presentation: 2887 / 23 – Patient-derived 3-dimensional models of pediatric tumors for in situ study of cancer biology, immunotherapy, and drug treatment
8 a.m.
Padraic P. Levings, Juan M. Urueña, Eric O. McGhee, Alex J. McGhee, Derek L. Hood, Kylie E. Van Meter, Steve H. Ghivizzani, Colin J. Anderson, Wallace G. Sawyer. University of Florida, Gainesville, FL
Session: PO.IM02.02. Combination Immunotherapies 3 (Section 23)
Presentation: 4075 / 8 – Overcoming glioma immunoediting and MHC class I loss during adoptive cellular therapy
1 p.m.
Tyler J. Wildes, Catherine T. Flores, Kyle Dyson, Connor Francis, Adam Grippin, Bayli Divita Dean, Duane A. Mitchell. University of Florida, Gainesville, FL
Session: PO.CL04.01. Special Populations / Biostatistics in Clinical Trials
Presentations: 4004 / 11 – Unique patient signatures underlie health disparities in ethnically diverse patients with pancreatic cancer
1 p.m.
Miles E. Cameron1, Patrick W. Underwood1, Jinping Lai1, Jennifer B. Permuth2, Andrew R. Judge1, Jose G. Trevino1. 1University of Florida Health Science Center, Gainesville, FL; 2Moffitt Cancer Center and Research Institute, Tampa, FL
Session: PO.MCB05.02. Epigenetic Changes as Molecular Markers (Section 33)
Presentation: 4339 / 27 – Critical role of Dnmt3b catalytic activity in prevention of oncogene-induced leukemias and lymphomas
1 p.m.
Katarina Lopusna1, Pawel Nowialis1, Staci L. Haney2, Ajay Abraham1, Jana Opavska1, Rene Opavsky1. 1University of Florida, Gainesville, FL; 2University of Nebraska Medical Center, Omaha, NE
Session: PO.ET03.05. Drug Resistance 5 (Section 10)
Presentation: 3800 / 5 – HDAC8 regulates plasticity and escape from therapy in BRAF mutant melanoma
1 p.m.
Michael Emmons1, Fernanda Flores1, John Koomen1, Edward Seto2, Jane Messina1, Eric Lau1, Jonathan Licht3, Keiran Smalley1. 1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL; 2George Washington University, Washington DC, DC; 3University of Florida, Gainesville, FL
Session: PO.TB06.08. Tumor Dormancy, Metastasis, and the Metastatic Niche (Section 6)
Presentation: 3759 / 12 – Host and neoplastic cell secretions of proteolytic enzymes potentiate metastasis
1 p.m.
Samantha S. Dykes, Henrietta O. Fasanya, Dietmar W. Siemann. University of Florida, Gainesville, FL
Session: PO.ET06.02 PI3K/AKT Inhibitors (Section 14)
Presentation: 3914 / 8 – mTOR pathway components dictate cell response to Src inhibitors in prostate cancer cells
1 p.m.
Yao Dai, Dietmar W. Siemann. Univ. of Florida College of Medicine, Gainesville, FL
FO08-0237. Challenges and Opportunities of International Consortia
5 p.m.
Room B401 – Georgia World CC
Folakemi T. Odedina, Ph.D., Moderator. Univ. of Florida Health Cancer Center, Orlando, FL
April 3
Session: PO.MC04.04. Regulation of Gene Expression in Cancer (Section 37)
Presentation: 5234 / 5 – Epigenetic control of heparanase expression through CRISPR/dCas9
8 a.m.
Guihua Zeng1, Fu-Sen Liang2, Lina Cui1. 1University of Florida, Gainesville, FL; 2Case Western Reserve University, Cleveland, OH
Session: PO.ET06.08. DNA Repair and Reactive Agents / HDAC / Demethylating Agents (Section 10)
Presentation: 4718 / 8 – Sr-4370, a potent and selective inhibitor of class I HDACs, suppresses AR signaling and in vivo prostate tumor growth
8 a.m.
Iqbal Mahmud1, Guimei Tian1, Jia Wang1, Ryan Stowe2, Zhiguang Huo1, Yushan Zhang1, Hamsa Thayek Purayil1, Eric Helm1, Theodore Drashansky1, Dorina Avram1, Yehia Daaka1, William R. Roush2, Daiqing Liao1. 1University of Florida College of Medicine, Gainesville, FL; 2The Scripps Research Institute, Jupiter, FL
Session: PO.ET07.01. Targeted Therapies (Section 14)
Presentation: 4837 / 25 – Role of Notchsignaling in human mucoepidermoid carcinoma and combined targeting of Notch and EGFR signaling as an anti-cancer strategy
8 a.m.
Wei Ni, Zirong Chen, Xin Zhou, Rongqiang Yang, Frederic Kaye, Lizi Wu. University of Florida, Gainesville, FL
Session: POTB06.07 Immune Cells in the Tumor Microenvironment 3 (Section 3)
Presentation: 4553 / 7 – Snail1 in primary breast tumors remotely regulates a pro-tumor immune response in the bone marrow
8 a.m.
Mathew Sebastian, Dongjiang Chen, Son Le, Duy Nguyen, Changwang Deng, Dan Jin, Nagheme Thomas, David Tran. University of Florida, Gainesville, FL
Session: POMCB04.01. Mechanisms and Consequences of Transcriptional Deregulation (Section 36)
Presentation: 5214 / 15 – Targeting the estrogen receptor pathway in luminal breast cancer through inhibition of p300/CBP
8 a.m.
Aaron Waddell, Iqbal Mahmud, Guimei Tian, Daiqing Liao. University of Florida, Gainesville, FL
Session: PO.MCB04.01. Mechanisms and Consequences of Transcriptional Deregulation (Section 36)
Presentation: 5222 / 23 – Repression of neuronal genes protects the pancreas from certain injuries and aberrant plasticity
8 a.m.
Julie K. Bray, Ola Elgamal, Lais Da Silva, Dhruvit Sutaria, Xiuli Liu, Kristianna Fredenburg, Thomas D. Schmittgen. University of Florida, Gainesville, FL